Blocking PD-L2 prevents senescent cell accumulation and age-related dysfunction.
Key claim: PD-L2 is upregulated on senescent cells and enables immune evasion; blocking PD-L2 reduces senescent-cell accumulation and restores insulin sensitivity and grip strength in aged mice.
Abstract
Senescent cells, which are normally cleared by the immune system but accumulate with age, contribute to multiple disorders including metabolic dysfunction and impaired fitness. While immune checkpoint inhibitors have been well studied in cancer, the role of programmed cell death ligand 2 (PD-L2) in non-cancerous, age-associated cellular senescence remains unclear. We found that PD-L2 is upregulated in isolated senescent human cells and during aging, and senolytics can remove age-associated, highly PD-L2-expressing senescent cells. Old PD-L2 knockout mice accumulate fewer senescent cells than old wild-type mice, and their insulin sensitivity and grip strength are greater. Anti-PD-L2 therapy restored insulin sensitivity in aged wild-type mice. PD-L2 acts as an immune checkpoint on senescent cells, allowing them to evade immune clearance and promoting their persistence during aging. Targeting PD-L2 in senescent cells may be a strategy for alleviating the age-related dysfunction associated with cellular senescence.
Why this matters
PD-L2 blockade reframes senescent-cell accumulation as partly an immune-evasion problem rather than solely a cell-intrinsic apoptosis-resistance problem, opening a checkpoint-inhibitor axis parallel to the D+Q/ABT-263/PCC1 senolytic chemistries. It also lands in an area where the oncology-derived checkpoint-blockade playbook already carries known autoimmune toxicity signals, so the gap between the mouse healthspan pitch (insulin sensitivity, grip strength) and any plausible human translation is unusually wide even for this field.